Transparency
We believe that transparency is key to building and maintaining confidence and trust in us, and in our medicines. Our relationship with healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of medicines. We want to ensure that patients and others have confidence that this relationship is open and transparent.
Our transfers of value to individual healthcare professionals and healthcare organisations from 2015, have been submitted to the ABPI disclosure database and IPHA disclosure website.
Patient Organisation Disclosure
Disclosure 2024
|
Year |
Recipient name / category |
Amount |
Purpose |
|
2024 |
Eczema Outreach Support (EOS) |
£15,000 |
Grant to Patient Organisation for addressing the unmet needs of neurodiverse children with eczema in the UK |
|
2024 |
Eczema Outreach Support (EOS) |
£250 |
Consultancy payment made to patient engaged via Patient Organisation. |
|
2024 |
Psoriasis Association |
£2,500 |
Sponsorship in the form of a financial contribution towards the Psoriasis Association Annual Conference 2024. |
|
2024 |
Allergy UK |
£384.62 |
Consultancy payment made to patient engaged via Patient Organisation. |
Disclosure 2023
|
Year |
Recipient name / category |
Amount |
Purpose |
|
2023 |
National Eczema Society |
£4,620 |
Support for the eczema awareness patient campaign |
|
2023 |
National Eczema Society |
£10,000 |
Charitable donation (Employee nomination following You Fit challenge) |
|
2023 |
Members of public (aggregate) |
£500 |
Fees for services |
Disclosure 2022
|
Year |
Patient Organisation Recipient Name |
Amount |
Purpose |
|
2022 |
National Eczema Society |
£24,000 |
Corporate membership / sponsorship |